Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/BBC3_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BBC3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BBC3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BBC3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BBC3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BBC3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BBC3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BBC3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009031614 | Prostate | Tumor | positive regulation of intracellular protein transport | 57/3246 | 160/18723 | 2.01e-08 | 7.03e-07 | 57 |
GO:007058517 | Prostate | Tumor | protein localization to mitochondrion | 47/3246 | 125/18723 | 5.20e-08 | 1.58e-06 | 47 |
GO:007265517 | Prostate | Tumor | establishment of protein localization to mitochondrion | 45/3246 | 120/18723 | 1.09e-07 | 2.89e-06 | 45 |
GO:001095018 | Prostate | Tumor | positive regulation of endopeptidase activity | 58/3246 | 179/18723 | 6.35e-07 | 1.32e-05 | 58 |
GO:009015017 | Prostate | Tumor | establishment of protein localization to membrane | 77/3246 | 260/18723 | 6.46e-07 | 1.33e-05 | 77 |
GO:200124415 | Prostate | Tumor | positive regulation of intrinsic apoptotic signaling pathway | 26/3246 | 58/18723 | 1.03e-06 | 1.99e-05 | 26 |
GO:004328017 | Prostate | Tumor | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 45/3246 | 129/18723 | 1.17e-06 | 2.21e-05 | 45 |
GO:200105617 | Prostate | Tumor | positive regulation of cysteine-type endopeptidase activity | 48/3246 | 148/18723 | 5.51e-06 | 8.48e-05 | 48 |
GO:190547515 | Prostate | Tumor | regulation of protein localization to membrane | 54/3246 | 175/18723 | 7.84e-06 | 1.16e-04 | 54 |
GO:007005918 | Prostate | Tumor | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 25/3246 | 63/18723 | 2.28e-05 | 2.88e-04 | 25 |
GO:000863717 | Prostate | Tumor | apoptotic mitochondrial changes | 36/3246 | 107/18723 | 3.26e-05 | 3.86e-04 | 36 |
GO:190547715 | Prostate | Tumor | positive regulation of protein localization to membrane | 35/3246 | 106/18723 | 6.46e-05 | 6.99e-04 | 35 |
GO:001082116 | Prostate | Tumor | regulation of mitochondrion organization | 44/3246 | 144/18723 | 6.75e-05 | 7.21e-04 | 44 |
GO:000183615 | Prostate | Tumor | release of cytochrome c from mitochondria | 22/3246 | 59/18723 | 2.05e-04 | 1.79e-03 | 22 |
GO:190374713 | Prostate | Tumor | regulation of establishment of protein localization to mitochondrion | 19/3246 | 50/18723 | 4.13e-04 | 3.16e-03 | 19 |
GO:001082213 | Prostate | Tumor | positive regulation of mitochondrion organization | 25/3246 | 74/18723 | 4.62e-04 | 3.47e-03 | 25 |
GO:000700616 | Prostate | Tumor | mitochondrial membrane organization | 35/3246 | 116/18723 | 4.65e-04 | 3.48e-03 | 35 |
GO:000691913 | Prostate | Tumor | activation of cysteine-type endopeptidase activity involved in apoptotic process | 25/3246 | 78/18723 | 1.11e-03 | 7.12e-03 | 25 |
GO:009055915 | Prostate | Tumor | regulation of membrane permeability | 25/3246 | 78/18723 | 1.11e-03 | 7.12e-03 | 25 |
GO:005120513 | Prostate | Tumor | protein insertion into membrane | 19/3246 | 57/18723 | 2.54e-03 | 1.41e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BBC3 | deletion | Frame_Shift_Del | | c.667delN | p.Arg223GlufsTer6 | p.R223Efs*6 | Q96PG8 | protein_coding | | | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
BBC3 | SNV | Missense_Mutation | rs769349350 | c.692G>A | p.Cys231Tyr | p.C231Y | Q96PG8 | protein_coding | tolerated_low_confidence(0.07) | benign(0.005) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BBC3 | SNV | Missense_Mutation | novel | c.649N>G | p.Gln217Glu | p.Q217E | Q96PG8 | protein_coding | deleterious_low_confidence(0.01) | benign(0.085) | TCGA-AJ-A3IA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BBC3 | SNV | Missense_Mutation | novel | c.776N>A | p.Cys259Tyr | p.C259Y | Q96PG8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.918) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BBC3 | SNV | Missense_Mutation | | c.685N>T | p.Gly229Cys | p.G229C | Q96PG8 | protein_coding | deleterious_low_confidence(0) | benign(0.182) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BBC3 | SNV | Missense_Mutation | novel | c.84N>G | p.Ile28Met | p.I28M | Q96PG8 | protein_coding | tolerated_low_confidence(0.1) | benign(0.009) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BBC3 | deletion | Frame_Shift_Del | novel | c.725delN | p.Gly242AlafsTer48 | p.G242Afs*48 | Q96PG8 | protein_coding | | | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
BBC3 | SNV | Missense_Mutation | rs747649341 | c.694A>G | p.Thr232Ala | p.T232A | Q96PG8 | protein_coding | tolerated_low_confidence(0.05) | benign(0.062) | TCGA-69-7973-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
BBC3 | SNV | Missense_Mutation | rs755414185 | c.698G>A | p.Arg233His | p.R233H | Q96PG8 | protein_coding | deleterious_low_confidence(0.01) | benign(0.044) | TCGA-MP-A4SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
BBC3 | SNV | Missense_Mutation | | c.656N>T | p.Pro219Leu | p.P219L | Q96PG8 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.625) | TCGA-18-3408-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |